In the lab, recombinant antibodies (rAbs) have many uses across biomedical and toxicological research. Monoclonal antibodies generated recombinantly are often used as biochemical markers or as methods for developing effective therapeutic treatments, targeting cancer, autoimmune disorders, and a broad range of other diseases.
From codon optimization for antibody sequences to production of desired antibodies, Azenta Life Sciences, formerly GENEWIZ equips researchers with a range of flexible and tailored solutions that save valuable time and accelerate innovation.
In recombinant antibody production, monoclonal antibodies are produced artificially through genetic engineering and other related techniques. Genetically engineered antibodies are specifically valuable in scientific research due to their ability to recognize individual antigenic sites on almost any molecule including drugs, hormones, microbial antigens, and cell receptors. Recombinant antibodies that react with cancer antigens, for example, can be used to identify cancer cells in tissue samples and ultimately fuel the the development of cancer-fighting drugs and therapies.